GSK's Jemperli Meets Primary Endpoint in Mid-Stage Rectal Cancer Study

GSK (LON:GSK) announced on Monday that its cancer immunotherapy, Jemperli, met its primary endpoint in a mid-stage clinical trial for a specific type of locally advanced rectal cancer. The study demonstrated a clinically meaningful rate of patients who had no detectable signs of cancer for one year or more following treatment.

Key Trial Findings

The positive results came from the interim analysis of the Phase II AZUR-1 trial. The study is evaluating Jemperli, known generically as dostarlimab, in patients whose rectal cancer tumors cannot properly repair DNA damage, a subtype known as dMMR/MSI-H.

GSK reported that the drug's safety and tolerability profile in the trial was consistent with previous studies in other solid tumors. The company plans to share the full data with global regulatory authorities for review.

Clinical and Market Significance

The dMMR/MSI-H subtype accounts for 5% to 10% of the approximately 730,000 global cases of rectal cancer diagnosed annually. The current standard of care for these patients often involves a combination of chemotherapy, radiation, and surgery, which can lead to life-altering consequences such as infertility or the permanent need for a colostomy bag.

Ad

Tumors with this genetic characteristic are known to be highly responsive to immunotherapies like Jemperli, which work by helping the body's immune system identify and attack cancer cells. A successful new treatment could offer a less invasive alternative for this patient population.

Commercial Outlook

Jemperli is a significant product for GSK and is already approved in the U.S. and U.K. for certain subtypes of endometrial cancer. The drug generated $1.1 billion in sales in 2025 and is considered a key contributor to GSK's long-term goal of achieving more than £40 billion ($53.52 billion) in sales by 2031.

For the rectal cancer indication, the U.S. Food and Drug Administration (FDA) has already granted the drug both Breakthrough Therapy and Fast Track designations, which are intended to expedite the development and review of treatments for serious conditions.